INSMED Inc (INSM) Stock
INSM has an Alpha Score of 21 out of 100 (poor), computed on Oct 29, 2026 from 2 of 4 sub-scores. 2 members of Congress disclosed 10 trades in INSM since 2022: 2 purchases and 8 sales, most recently Josh Gottheimer (partial sale, Jun 10, 2026). 8 of the hedge funds AlphaScala tracks reported INSM in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $626.71M. Company insiders reported 0 open-market buys and 5 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
What is INSM's Alpha Score?
How it works →Alpha Score of 21 reflects poor overall profile with poor momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 29, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded INSMED Inc (INSM)?
Most recent: Josh Gottheimer (partial sale, Jun 10, 2026); records start Dec 6, 2022.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Josh Gottheimer D-NJ · House | 2026-06-10 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-10-03 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-09-22 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-08-08 | partial sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2025-07-07 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-06-16 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-04-09 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-06-21 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all INSM political trades →Which hedge funds own INSM?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 5.88M | $626.71M | +4% |
| Citadel Ken Griffin | 2.56M | $272.62M | +17% |
| Maverick Capital Lee Ainslie | 2.15M | $229.31M | NEW |
| Millennium Management Israel Englander | 2.05M | $218.36M | +77% |
| Duquesne Family Office Stanley Druckenmiller | 1.42M | $151.90M | +23% |
| Point72 Steve Cohen | 537K | $57.25M | NEW |
| Marshall Wace | 502K | $53.52M | +61% |
| Bridgewater Associates Ray Dalio | 455K | $48.55M | +54% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are INSMED Inc insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 9, 26 | Brennan David R | Director | SELL | 25.0K | $3.1M |
| Aug 17, 26 | Sharoky Melvin Md | Director | SELL | 5.0K | $638K |
| Aug 10, 26 | Adsett Roger | Chief Operating Officer | SELL | 239.8K | $32.0M |
| Aug 6, 26 | Flammer Martina M.D. | Chief Medical Officer | SELL | 8.9K | $1.1M |
| Aug 6, 26 | Flammer Martina M.D. | Chief Medical Officer | SELL | 18.3K | $2.4M |
| Jul 23, 26 | Lewis William | Chair and CEO | SELL | 4.8K | $510K |
| Jul 23, 26 | Lewis William | Chair and CEO | SELL | 5.9K | $625K |
| Apr 16, 26 | Lewis William | Chair and CEO | SELL | 2.2K | $321K |
| Apr 16, 26 | Lewis William | Chair and CEO | SELL | 5.4K | $773K |
| Apr 16, 26 | Lewis William | Chair and CEO | SELL | 2.3K | $326K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are INSM's key statistics?
Key statistics as of Nov 4, 2026
How does INSM's valuation compare with the Healthcare sector?
| Metric | INSM | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -76.94% | 4.64% | 150 |
| Return on equity | -111.26% | 6.41% | 169 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
INSM price chart
Powered by TradingViewWhat does INSMED Inc do?
Insmed Inc. is a global biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with serious and rare diseases, particularly those affecting the lungs. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the United States for treating Mycobacterium avium complex (MAC) lung disease in adults with limited treatment options, as part of a combination regimen. The company is advancing a pipeline that includes Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor targeting bronchiectasis and other neutrophil-mediated inflammatory conditions, and Treprostinil Palmitil Inhalation Powder, an inhaled prodrug for pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. Insmed Inc. operates in the biotechnology sector, focusing on unmet needs in respiratory and rare pulmonary disorders through rigorous clinical research and patient-centric approaches. Founded in 1988 and headquartered in Bridgewater, New Jersey, the company maintains corporate offices and research sites worldwide to support its mission of delivering first- and best-in-class treatments.